Tandem Diabetes Care Inc (TNDM) · Aug 6, 2026 · Company update

Revenue missed consensus, but margins and EPS improved meaningfully.

Revenue missed consensus, but margins and EPS improved meaningfully.

The quarter came in below the revenue bar. Published estimates were roughly $260.1 million of revenue and a $0.32–$0.33 per-share loss; Tandem delivered $254.6 million and a $0.31 loss, meaning a modest revenue miss but a small EPS beat.

$ millions, except per-share dataQ2 2026Q2 2025Published expectation
Sales254.6240.7~260.1
Net loss(21.2)(52.4)—
Net loss per share(0.31)(0.78)~(0.32)–(0.33)
Adjusted EBITDA6.4(1.9)—
Free cash flow(38.7)(15.7)—

The quality of earnings improved, but the top line was not strong enough. Worldwide sales rose 6% year over year, or 5% in constant currency, with U.S. sales up 5%; however, U.S. pump revenue fell 3%, while growth came primarily from supplies and other revenue, up 14% (Sales by Geography). Gross profit increased to $144.8 million from $125.9 million, lifting gross margin to roughly 57% from 52% (Income Statement).

Profitability progress was real, though partly aided by an easier comparison. GAAP operating loss narrowed to $13.8 million from $51.8 million, and adjusted EBITDA turned positive at $6.4 million versus negative $1.9 million (Table D — Reconciliation of GAAP versus Non-GAAP Financial Results). The prior-year quarter included a $20.0 million litigation charge, so the year-over-year improvement overstates the underlying acceleration; even excluding that charge, operating loss improved from $31.9 million to $13.8 million.

Cash generation weakened despite the better income statement. Free cash flow was negative $38.7 million versus negative $15.7 million a year earlier, while cash and short-term investments rose to $456.0 million from $292.7 million largely alongside a sharp increase in convertible senior notes to $602.6 million from $310.0 million (Table D; Table A — Balance Sheets). That leaves the company better funded, but not yet self-funding.

Net read: a mixed quarter leaning slightly negative versus expectations. The EPS beat and operating improvement are constructive, but they do not fully offset the revenue miss, weaker free cash flow, and the fact that pump growth remains soft in the United States. The filing also provides no new numerical 2026 guidance in the furnished release, so the market still needs management’s broader guidance discussion to determine whether the shortfall is timing-related or a more meaningful demand issue.

Original filing on SEC EDGAR

More Tandem Diabetes Care Inc news

Revenue missed consensus, but margins and EPS improved meaningfully. | TNDM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.